Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Martijn van Gerven to share Foundation’s work on AMR at Global AMR R&D Hub Annual Stakeholder Group Meeting

The Access to Medicine Foundation’s Research Programme Manager, Martijn van Gerven, will be attending the AMR R&D Hub’s Annual Stakeholder Group Meeting, where he will share insights from the Foundation’s work on antimicrobial resistance (AMR).

Date

26 November 2024

Location

Berlin, Germany

As a member of the Global AMR R&D Hub, Foundation has been invited to participate in the Annual Stakeholder Group Meeting on 26 November, 2024. The event will bring together executives, industry experts, and global health leaders committed to addressing antimicrobial resistance. Martijn van Gerven, the Foundation’s Research Programme Manager for its AMR programme, will attend the meeting in Berlin.

Martijn will draw from the Foundation’s work in its AMR Programme, including highlights from the recently published research and development (R&D) paper, which focuses on how companies can improve access and stewardship planning to ensure newly developed antibiotics and antifungals reach patients who need them the most.

He will also share key takeaways from the Foundation's Expert Review Committee meeting on 17 October, where new proposals for changes to the AMR programme’s methodology framework were introduced to better assess companies' efforts to combat drug resistance. Representatives from pharmaceutical companies in attendance will find this particularly useful in gaining insights on access and stewardship planning in low-and middle-income countries (LMICs).

About the AMR R&D Hub

The Global AMR R&D Hub is a partnership of countries, non-governmental donor organisations and intergovernmental organisations to address challenges and improve coordination and collaboration in global AMR R&D using a One Health approach.

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Resource Centre

Explore our research reports and publications
Featured Research

How can pharma get the few promising drugs in development to patients battling superbugs?

23 May 2024
Media

Faced with fewer superbug-beating drugs, how can pharma get more promising medicines to patients?

28 May 2024
Research

How have companies responded to their AMR Benchmark Opportunities?

21 November 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved